Lourdes Rodriguez Fernandez-Freire
Overview
Explore the profile of Lourdes Rodriguez Fernandez-Freire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cayuela L, Pereyra-Rodriguez J, Hernandez-Rodriguez J, Rodriguez Fernandez-Freire L, Cayuela A
Med Clin (Barc)
. 2024 Nov;
164(3):117-122.
PMID: 39562231
Objectives: This study aimed to investigate the prevalence of psoriasis in Spain from 2018 to 2022 and analyze trends by sex and age groups. Methods: We used the Primary Care...
2.
Puig L, Izu Belloso R, Rivera-Diaz R, Mollet Sanchez J, Rodriguez Fernandez-Freire L, Sahuquillo-Torralba A, et al.
Dermatology
. 2024 Jul;
240(5-6):778-792.
PMID: 39019021
Introduction: Generalized pustular psoriasis (GPP) is a chronic, rare, and potentially life-threatening skin condition characterized by flares comprising widespread sterile pustules and systemic inflammation. Both the rarity and heterogeneity of...
3.
Berenguer-Ruiz S, Aparicio-Dominguez M, Herranz-Pinto P, Ruiz-Villaverde R, Lopez-Ferrer A, Santos-Juanes J, et al.
J Eur Acad Dermatol Venereol
. 2023 Aug;
37(12):2517-2525.
PMID: 37625815
Background: Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate-to-severe plaque psoriasis. Real-world evidence on the...
4.
Ortiz Alvarez J, Rodriguez Fernandez-Freire L, Hernandez-Rodriguez J, Barabash-Neila R, Duran-Romero A, Morillo-Andujar M, et al.
Arch Dermatol Res
. 2022 Nov;
315(4):1045-1048.
PMID: 36316510
No abstract available.
5.
Ruiz-Villaverde R, Rodriguez Fernandez-Freire L, Font-Ugalde P, Galan-Gutierrez M
J Clin Med
. 2022 Sep;
11(17).
PMID: 36079026
Tildrakizumab (TIL) binds selectively to the p19 subunit of interleukin 23. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-12/23 class)...
6.
Del Alcazar E, Lopez-Ferrer A, Martinez-Domenech A, Julia M, Ruiz-Villaverde R, Rodriguez Fernandez-Freire L, et al.
J Dermatolog Treat
. 2022 May;
33(6):2878-2880.
PMID: 35593480
No abstract available.
7.
Del Alcazar E, Lopez-Ferrer A, Martinez-Domenech A, Ruiz-Villaverde R, Llamas-Velasco M, Rocamora V, et al.
Dermatol Ther
. 2021 Nov;
35(2):e15231.
PMID: 34820971
Data on the effectiveness and safety of a drug in real-world clinical practice complement the evidence from clinical trials, which are carried out in a different setting. Little has been...
8.
Ortiz-Alvarez J, Lebron-Martin J, Rodriguez Fernandez-Freire L, Zulueta Dorado T, Morillo J
Eur J Case Rep Intern Med
. 2021 Jul;
8(7):002652.
PMID: 34268272
Learning Points: Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) is a recently devised umbrella term for autoimmune diseases caused by adjuvants.Aesthetic procedures, which are increasingly common, may be a cause of...
9.
Baniandres-Rodriguez O, Vilar-Alejo J, Rivera R, Carrascosa J, Dauden E, Herrera-Acosta E, et al.
J Am Acad Dermatol
. 2020 Oct;
84(2):513-517.
PMID: 33122022
No abstract available.
10.
Rodriguez Fernandez-Freire L, Galan-Gutierrez M, Armario-Hita J, Perez-Gil A, Ruiz-Villaverde R
Dermatol Ther
. 2020 Apr;
33(3):e13344.
PMID: 32227659
No abstract available.